Mitchell P. Rales
Net Worth

Last updated:

What is Mitchell P. Rales net worth?

The estimated net worth of Mr. Mitchell P. Rales is at least $389,076,887 as of 26 Sep 2025. He owns shares worth $253,541,041 as insider, has earned $135,535,824 from insider trading and has received compensation worth at least $22 in companies like Danaher Corporation, Enovis Corporation, Colfax Corporation etc.

What is the salary of Mitchell P. Rales?

Mr. Mitchell P. Rales salary is $1 per year as Co-Founder & Chairman in Enovis Corporation. He also receives $1 as Co-Founder & Chairman in Colfax Corporation and salaries from other companies.

What stocks does Mitchell P. Rales currently own?

As insider, Mr. Mitchell P. Rales owns shares in 2 companies:

Company Title Shares Price per share Total value
Colfax Corporation (CFXA) Co-Founder & Chairman 1,170,201 $177.71 $207,956,420
Colfax Corporation (CFX) Co-Founder & Chairman 1,167,041 $39.06 $45,584,621

What does Colfax Corporation do?

Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment, including cutting, joining, and automated welding products, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the infrastructure, wind power, marine/life sciences, pipelines, mobile/off-highway equipment, oil, gas, and mining markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, spine surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and direct and independent distributors under the DJO brand. Colfax Corporation was founded in 1860 and is based in Wilmington, Delaware.

CFXA logo
CFXA
Colfax Corporation
$177.71

What does Colfax Corporation do?

Colfax Corporation operates as a diversified technology company worldwide. The company operates in two segments, Fabrication Technology and Medical Technology. The Fabrication Technology segment formulates, develops, manufactures, and supplies consumable products and equipment for use in cutting, joining, and automated welding, as well as gas control equipment. It also provides welding consumables comprising electrodes, cored and solid wires, and fluxes using a range of specialty and other materials; and cutting consumables, such as electrodes, nozzles, and shields and tips. This segment sells its products through independent distributors and direct sales to the general industry, construction, infrastructure, transportation, energy, renewable energy, and medical and life sciences markets principally under the ESAB brand. The Medical Technology segment develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. This segment sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. Colfax Corporation was founded in 1860 and is headquartered in Wilmington, Delaware.

CFX logo
CFX
Colfax Corporation
$39.06

Mitchell P. Rales insider trading

Colfax Corporation

Mr. Mitchell P. Rales has made only one insider trade between 2008-2021, according to the Form 4 filled with the SEC. He purchased 62,500 units of CFX stock worth $2,914,375 on 4 Aug 2021.

As of 26 Sep 2025 he still owns at least 1,167,041 units of CFX stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock, par value $.001 62,500 $46.63 $2,914,375
Purchase
Common Stock, par value $.001 62,500 $46.59 $2,911,563
Purchase
Common Stock, par value $.001 125,200 $45.87 $5,743,300
Purchase
Tangible Equity Units (Right to Buy) 400,000 $100 $40,000,000
Purchase
Common Stock, par value $.001 110,100 $38.8 $4,271,770
Purchase
Common Stock, par value $.001 151,500 $38.11 $5,773,665
Purchase
Common Stock, par value $.001 45,000 $47.62 $2,142,900
Purchase
Common Stock, par value $.001 455,000 $46.12 $20,984,600
Purchase
Common Stock, par value $.001 3,800 $62.18 $236,284
Purchase
Common Stock, par value $.001 16,300 $45.15 $735,880
Purchase
Common Stock, par value $.001 9,000 $29.1 $261,864
Purchase
Common Stock, par value $.001 15,000 $29.2 $438,060
Purchase
Common Stock, par value $.001 7,500 $29.75 $223,110
Purchase
Common Stock, par value $.001 2,170,139 $23.04 $50,000,003
Purchase
Common Stock, par value $.001 25,000 $25.45 $636,175
Sale
Common Stock, par value $.001 7,529,768 $18 $135,535,824

Colfax Corporation

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock, par value $.001 62,500 $46.63 $2,914,375
Purchase
Common Stock, par value $.001 62,500 $46.59 $2,911,563
Purchase
Common Stock, par value $.001 125,200 $45.87 $5,743,300

Danaher key executives

Danaher Corporation executives and other stock owners filed with the SEC:

  • Mr. Brian W. Ellis Senior Vice President, Gen. Counsel & Chief Compliance Officer
  • Mr. Daniel A. Raskas J.D. Senior Vice President of Corporation Devel.
  • Mr. Joakim Weidemanis (56) Executive Vice President
  • Mr. Matthew E. Gugino C.F.A., CPA, CFA, CPA Vice President of Investor Relations
  • Mr. Matthew R. McGrew (53) Chief Financial Officer & Executive Vice President
  • Mr. Mitchell P. Rales Co-Founder & Director
  • Mr. Rainer M. Blair (61) Pres, Chief Executive Officer & Director
  • Mr. Robert S. Lutz Chief Accounting Officer & Senior Vice President
  • Mr. Steven M. Rales Co-Founder & Chairman
  • Mr. Thomas P. Joyce Jr. (64) Senior Advisor